Our goal is to study the effect of intravenous and oral contrast on the SUV in 18F-FDG PET-CT. The results will contribute to the adequate quantification of 18F-FDG-uptake in different clinical circumstances and the efficient use of combined PET-CT…
ID
Source
Brief title
Condition
- Other condition
- Respiratory and mediastinal neoplasms malignant and unspecified
Synonym
Health condition
lymfomen (HD en NHL), cervixcarcinoma
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
De differences in SUV measurements with and without contrast agents will be
determined.
Secondary outcome
not appilcable
Background summary
In 18F-FDG positron emission tomography there is attenuation of tissue,
resulting in weakening of the signal. To correct the weakening of the signal is
an attenuation algrythm necessary. In case of teh combined PEt-CT, the
attenuation map is based on the HU values of the CT images.
Intravenous and oral contrast attenuate more (higher HU values) due to their
high atomic numbers. This higher attenuation leads to overcorrection of the
standard uptake value (SUV) of 18F-FDG, the measurement of radioactive sugar
uptake in tissue. The exact determination as well as detecting small changes of
SUV becomes more and more important in daily practice. Since the effect of
contrast agents on SUV is not yet evaluated, scientific studies advise against
the use of contrast agents in PET-CT. This results in a less patient friendly
and less effective imaging protocol.
Study objective
Our goal is to study the effect of intravenous and oral contrast on the SUV in
18F-FDG PET-CT. The results will contribute to the adequate quantification of
18F-FDG-uptake in different clinical circumstances and the efficient use of
combined PET-CT imaging.
Study design
10 patients undergo the referred PET-CT (low dose) investigation without any
contrast agents, followed by administration of oral contrast and a repeated
imaging protocol with intravenous contrast as well.
10 patients undergo the referred PET-CT (diagnostic dose) investigation without
any contrast agents, followed by administration of oral contrast and a repeated
imaging protocol with intravenous contrast as well.
Reinjection of 18F-FDG is not necessary.
Study burden and risks
There are no known health hazards in connection with one extra CT
investigation.
P. O. Box 22770
1100DD Amsterdam
Nederland
P. O. Box 22770
1100DD Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
-18F-FDG PET-CT indication with i.v. and/ or oral contrast; eg. staging, restaging, therapy monitoring or radiotherapy planning of malignancy
-expected circumscript malignancy (eg. lung cancer, lymphomas or cervical cancer)
-informed consent
Exclusion criteria
Age < 18years
Pregnancy
Renal insufficiency
Contrast allergy
Calustrophoby
Respiratory assistance or scanning under total anaesthesia
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL24420.018.08 |